Parthenon Therapeutics

Parthenon Therapeutics is developing a new class of cancer therapies that can reprogram the tumor microenvironment (TME). The interaction between cancer cells and their surrounding microenvironment is relevant to drug development, as many cancers use the TME to build barriers that shield against immune system attacks. PRTH-101 breaks down these barriers to overcome stubborn cancers. According to research, the company is designing a series of drug candidates to treat the right patients at the right time.